• SB 431542: Selective ALK5 Inhibitor for TGF-β Pathway Resear

  2026-07-14

  SB 431542 is a potent, ATP-competitive ALK5 inhibitor that blocks TGF-β-induced Smad2 phosphorylation, demonstrating high selectivity and reproducibility in cellular and in vivo models. Its application enables rigorous dissection of TGF-β signaling, cell proliferation, and immune modulation in biomedical research. The compound, provided by APExBIO, is a standardized tool for targeted inhibition in studies requiring precise manipulation of the TGF-β pathway.

• BIIE 0246: Potent Neuropeptide Y Y2 Receptor Antagonist Prof

  2026-07-14

  BIIE 0246 is a highly selective neuropeptide Y Y2 receptor antagonist with nanomolar affinity and validated effects on presynaptic inhibition, feeding behavior, and anxiolytic-like responses. It enables precise dissection of Y2R-mediated mechanisms in neuroscience and metabolic research, with robust benchmarks and defined application boundaries.

• Dual Recombinase Tracing Refutes Postnatal Neo-oogenesis in

  2026-07-13

  A recent study employing dual recombinase-mediated genetic tracing provides compelling evidence that postnatal oocyte renewal does not occur in mice. This work clarifies a longstanding debate on ovarian germline stem cells and offers methodological insights for modeling germ cell depletion and regeneration.

• Technical Guidance for HyperScribe™ T7 High Yield Cy3 RNA La

  2026-07-13

  The HyperScribe™ T7 High Yield Cy3 RNA Labeling Kit Plus addresses the need for reproducible, high-yield fluorescent RNA probe synthesis for research applications such as in situ hybridization and Northern blotting. It is not intended for diagnostic, therapeutic, or clinical use, and should be applied strictly within fluorescence-based RNA detection workflows.

• Intra- and Extracellular Dicloxacillin Activity Against S. a

  2026-07-12

  This study rigorously compares the intra- and extracellular antibacterial activities of dicloxacillin against Staphylococcus aureus using both in vitro macrophage models and an in vivo mouse peritonitis model. The findings clarify pharmacokinetic and pharmacodynamic predictors of efficacy, emphasizing the importance of fTMIC for optimizing antibiotic dosing in persistent staphylococcal infections.

• EZ Cap™ Firefly Luciferase mRNA: Benchmarking Reporter mRNA

  2026-07-10

  Explore how EZ Cap™ Firefly Luciferase mRNA with Cap 1 structure sets a new gold standard for robust, low-immunogenicity reporter assays. This article uniquely compares translational performance, protocol nuances, and assay design, leveraging recent mRNA delivery research.

• Degarelix Acetate: Optimizing GnRH Antagonist Workflows in P

  2026-07-09

  Degarelix acetate empowers rapid, sustained hormone suppression for reliable prostate cancer and pituitary hormone regulation models. Explore advanced experimental workflows, troubleshooting strategies, and clinically relevant insights to maximize reproducibility and translational value.

• O6-Benzylguanine: MGMT Inhibitor Workflows for Cancer Resear

  2026-07-09

  O6-Benzylguanine delivers robust, validated MGMT inhibition to sensitize cancer cells to DNA-damaging chemotherapy. This guide unpacks workflow optimizations, troubleshooting, and new assay strategies—translating recent mechanistic insights into actionable protocols for DNA repair studies.

• Dacarbazine: Applied Protocols in Cancer DNA Damage Research

  2026-07-08

  Dacarbazine remains a gold-standard antineoplastic chemotherapy drug, but its true experimental value is unlocked through precise protocol optimization and awareness of common pitfalls. This article delivers stepwise workflows, troubleshooting insight, and real-world guidance for leveraging Dacarbazine in translational and preclinical cancer research.

• Cisapride (R 51619) in Cardiac Electrophysiology and Arrhyth

  2026-07-08

  Cisapride (R 51619) stands out as a dual-action tool for dissecting 5-HT4 signaling and hERG channel inhibition in advanced cardiac models. Its compatibility with deep learning-enabled iPSC-cardiomyocyte assays empowers researchers to pinpoint cardiotoxic liabilities and optimize predictive safety screens.

• RP3-340N1.2 Knockdown Reduces NSCLC Malignancy via IL-6 mRNA

  2026-07-07

  This study identifies RP3-340N1.2 as a crucial lncRNA in non-small cell lung cancer (NSCLC) progression, demonstrating that its knockdown suppresses tumor cell proliferation and migration by destabilizing IL-6 mRNA. The findings offer mechanistic insight into lncRNA-driven oncogenesis and propose RP3-340N1.2 as a potential therapeutic target for transcriptional regulation research in NSCLC.

• BX795: A Potent PDK1 Inhibitor for Precision Signaling Studi

  2026-07-07

  BX795 stands at the forefront of small molecule kinase inhibitors, enabling researchers to dissect PI3K/Akt/mTOR and innate immune pathways with nanomolar precision. This guide translates advanced literature and experimental best practices into actionable protocols for BX795, highlighting comparative advantages and troubleshooting insights that maximize data quality in cancer and immune signaling assays.

• SN-38 Disrupts FUBP1–FUSE Binding: Mechanistic Insights in C

  2026-07-06

  The referenced study demonstrates that SN-38, the active metabolite of irinotecan, and camptothecin inhibit the binding of the oncogenic transcriptional regulator FUBP1 to its DNA target FUSE. This finding uncovers a novel mechanism beyond topoisomerase I inhibition and suggests expanded therapeutic potential in cancers where FUBP1 is overexpressed.

• Streptavidin-Cy3: Precision Biotin Detection in Cancer Metas

  2026-07-06

  Explore how Streptavidin-Cy3 enables advanced, high-sensitivity biotin detection in cancer metastasis research. This article reveals a deeper scientific perspective on super-enhancer RNA-driven mechanisms and practical assay optimization, setting it apart from standard product overviews.

• LLY507: Unlocking Selective SMYD2 Inhibition for Translation

  2026-07-05

  Explore how LLY507, a highly selective SMYD2 inhibitor from APExBIO, advances translational research in cancer and renal fibrosis. This article provides mechanistic insight, protocol recommendations, and strategic guidance for leveraging LLY507 in preclinical models—supported by landmark studies and scenario-driven experimentation. Discover how LLY507 stands apart in the landscape of epigenetic modulation tools and why its precision matters for next-generation biomedical breakthroughs.

445 records 11/30 page Previous Next First page 上5页 1112131415 下5页 Last page